The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 23, Issue 2, Pages 107-116
Publisher
Informa UK Limited
Online
2018-12-22
DOI
10.1080/14728222.2019.1559825
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Farnesoid X receptor modulators 2014-present: a patent review
- (2018) Valentina Sepe et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation
- (2018) Zhibo Gai et al. MOLECULAR PHARMACOLOGY
- Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress
- (2018) Sujuan Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vascular liver lesions: contemporary views on long-recognized entities
- (2018) Christine Sempoux et al. VIRCHOWS ARCHIV
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury
- (2018) Jin-Bo Zhu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy
- (2018) Yosra M. Magdy et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Clinical significance of farnesoid X receptor expression in thyroid neoplasia
- (2017) Constantinos Giaginis et al. Future Oncology
- A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis
- (2017) Paolo Comeglio et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
- (2017) Xiaoxin X. Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy
- (2017) Andi Marquardt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Farnesoid X receptor regulates the growth of renal adenocarcinoma cells without affecting that of a normal renal cell-derived cell line
- (2017) Tomofumi Fujino et al. JOURNAL OF TOXICOLOGICAL SCIENCES
- Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in mice
- (2017) Jianshu Gao et al. Molecular Medicine Reports
- Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation
- (2017) Yimeng Zhang et al. TOXICOLOGY
- Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
- (2017) Zhibo Gai et al. Scientific Reports
- Dihydroartemisinin counteracts fibrotic portal hypertensionviafarnesoid X receptor-dependent inhibition of hepatic stellate cell contraction
- (2016) Wenxuan Xu et al. FEBS Journal
- Role of Bile Acid–Regulated Nuclear Receptor FXR and G Protein–Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease)
- (2016) Moshe Levi HYPERTENSION
- Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice
- (2016) Young Sun Kang et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy
- (2016) Baoshang Zhou et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys bySpirulina fusiformisin a rat model
- (2016) Sherry Joseph Martin et al. RENAL FAILURE
- Uninephrectomy-Induced Lipolysis and Low-Grade Inflammation Are Mimicked by Unilateral Renal Denervation
- (2016) Denis Arsenijevic et al. Frontiers in Physiology
- Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
- (2016) Kai Zhao et al. Scientific Reports
- Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases
- (2015) John Y.L. Chiang HEPATOLOGY
- Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
- (2015) Zhibo Gai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity
- (2015) Sarah J. Glastras et al. Nutrition & Metabolism
- Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney
- (2014) Zhibo Gai et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
- (2014) Eun Hui Bae et al. PLoS One
- Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice
- (2014) Xiaoyan Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of N-Myc downstream regulated gene 2 by bile acids
- (2013) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice
- (2013) Peter Fickert et al. HEPATOLOGY
- Chronic kidney disease: global dimension and perspectives
- (2013) Vivekanand Jha et al. LANCET
- FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl Rats
- (2013) Yohannes T. Ghebremariam et al. PLoS One
- Bile Acids Acutely Stimulate Insulin Secretion of Mouse -Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition
- (2012) M. Dufer et al. DIABETES
- Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats
- (2012) Zhijuan Hu et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Inflammation in Diabetic Nephropathy
- (2012) Andy K. H. Lim et al. MEDIATORS OF INFLAMMATION
- Chapter 3: Management of progression and complications of CKD
- (2012) Kidney International Supplements
- Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
- (2011) J. Prawitt et al. DIABETES
- Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression and Arachidonic Acid Metabolism in Rat Kidney and Liver
- (2011) B. N. M. Zordoky et al. DRUG METABOLISM AND DISPOSITION
- Chronic kidney disease
- (2011) Andrew S Levey et al. LANCET
- The bile acid sensor FXR regulates insulin transcription and secretion
- (2010) Barbara Renga et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE −/− Mice With Chronic Kidney Disease
- (2010) Shinobu Miyazaki-Anzai et al. CIRCULATION RESEARCH
- Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
- (2010) X. X. Wang et al. DIABETES
- The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity
- (2010) Iuliana Ristea Popescu et al. FEBS LETTERS
- Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease
- (2010) Jiao Mu et al. JOURNAL OF NEPHROLOGY
- Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
- (2009) Brenton Flatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Coordinated Regulation of Dimethylarginine Dimethylaminohydrolase-1 and Cationic Amino Acid Transporter-1 by Farnesoid X Receptor in Mouse Liver and Kidney and Its Implication in the Control of Blood Levels of Asymmetric Dimethylarginine
- (2009) J. Li et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle
- (2008) Taiki Kida et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Dimethylarginine Dimethylaminohydrolase Overexpression Enhances Insulin Sensitivity
- (2008) Karsten Sydow et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
- (2008) Cédric Langhi et al. FEBS LETTERS
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray
- (2007) Hiroyuki Higashiyama et al. ACTA HISTOCHEMICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now